Viewing Study NCT01510860


Ignite Creation Date: 2025-12-25 @ 2:04 AM
Ignite Modification Date: 2025-12-26 @ 12:43 AM
Study NCT ID: NCT01510860
Status: COMPLETED
Last Update Posted: 2019-05-07
First Post: 2012-01-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
Sponsor: Dr. Falk Pharma GmbH
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module